Abstract

Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. The pathophysiology of MM-induced angiogenesis involves both direct production of angiogenic cytokines by plasma cells and their induction within the bone marrow microenvironment. An improved understanding of the importance of angiogenesis-related signaling in MM has allowed for the rational use of antiangiogenic therapies in this tumor. This review article summarizes the literature data concerning the employment of the most important antiangiogenic therapeutic agents actually used in preclinical models and clinical settings for the treatment of MM.

Keywords: Angiogenesis, antiangiogenesis, bortezomib, lenalinomide, multiple myeloma, thalidomide, thyrosine kinase inhibitors, zoledronic acid, chorioallantoic membrane, Monoclonal gammopathy of undetermined significance, Platelet-derived growth factor receptor, Hypoxia inducible factor 1 alpha, chorioallantoic membrane.